This Plain Language Summary of Publication article (PLSP) from Future Oncology evaluated atezolizumab (immunotherapy) versus single-agent chemotherapy (vinorelbine or gemcitabine) as first-line treatment for advanced or metastatic non-small cell lung cancer (NSCLC) patients who were unsuitable for standard platinum-based chemotherapy due to weakness, age, or other medical conditions.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study’ and was published in The Lancet.

Visit The Lancet using the link to read the original article.